Rate of development of clinical definite multiple sclerosis 10 years [clinicaltrials_resource:fbb183e2b1ac96c5451e1f1afc5b7703]
Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Rate of development of clinical definite multiple sclerosis 10 years [clinicaltrials_resource:fbb183e2b1ac96c5451e1f1afc5b7703]
Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
Bio2RDF identifier
fbb183e2b1ac96c5451e1f1afc5b7703
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fbb183e2b1ac96c5451e1f1afc5b7703
measure [clinicaltrials_vocabulary:measure]
Rate of development of clinical definite multiple sclerosis
time frame [clinicaltrials_vocabulary:time-frame]
description
Initiation of treatment with I ...... drome in high risk individuals
identifier
clinicaltrials_resource:fbb183e2b1ac96c5451e1f1afc5b7703
title
Rate of development of clinical definite multiple sclerosis 10 years
@en
type
label
Rate of development of clinica ...... 183e2b1ac96c5451e1f1afc5b7703]
@en